Diabetes Type-1: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Diabetes Type-1: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

  • 285 Pages | Published On: 10-Jul-18 | Format:PDF | Last Updated: Updation in process
  • GervanoRA’s Market Estimation report “Diabetes Type-1: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)” analyzed the current and upcoming opportunities in the Diabetes Type-1 area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Diabetes Type-1 industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Diabetes Type-1 area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Diabetes Type-1 Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed drugs to provide a brief understanding about the market opportunities in the Diabetes Type-1 competitive environment. We have also prognosticated the Diabetes Type-1 market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Epidemiology and Epidemiology forecast 2018– 2025
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Timelines
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future).

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    2.1. MARKET SNAPSHOT, 2017-2028
    2.2. KEY EVENTS IN TYPE-1 DIABETES MARKET, 2000-2030
    2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
    2.4. KEY MAJOR FINDINGS
    2.4.1. DRIVERS
    2.4.2. RESTRAINTS
    2.4.1. UNMET NEEDS AND OPPORTUNITY
    3 DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.1.1. CLINICAL MANIFESTATIONS
    3.1.2. PATHOGENESIS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4 MARKET OVERVIEW
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
    4.5. NEW DRUG APPROVALS (EMA) SINCE 2010
    4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5 PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.1.7. INACTIVE MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. ESTIMATED APPROVAL TIMELINES
    5.6.1. METHODOLOGY
    5.6.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    6 GLOBAL TYPE-1 DIABETES THERAPEUTIC MARKET BY DRUG CLASS
    6.1. INSULIN
    6.1.1. NOVOLOG, FIASP (INSULIN ASPART)
    6.1.2. APIDRA (INSULIN GLULISINE)
    6.1.3. HUMALOG (INSULIN LISPRO)
    6.1.4. AFREZZA (INSULIN INHALED)
    6.1.5. HUMULIN R, NOVOLIN R (REGULAR INSULIN)
    6.1.6. LEVEMIR (INSULIN DETEMIR)
    6.1.7. LANTUS, LANTUS SOLOSTAR, TOUJEO, BASAGLAR (INSULIN GLARGINE)
    6.1.8. TRESIBA (INSULIN DEGLUDEC)
    6.1.9. NOVOLOG 70/30 (INSULIN ASPART PROTAMINE/ ASPART)
    6.1.10. HUMALOG 75/25 (INSULIN LISPRO PROTAMINE/LISPRO)
    6.1.11. RYZODEG (INSULIN DEGLUDEC/ASPART)
    6.2. OTHER TYPE-1 ANTI-DIABETES AGENTS
    6.2.1. AMYLINOMIMETICS
    6.2.2. HYPOGLYCEMIA ANTIDOTES
    7 GLOBAL TYPE-1 DIABETES THERAPEUTIC MARKET BY ROA
    7.1. ORALS
    7.1.1. MARKET TRENDS AND GROWTH FACTORS
    7.1.2. UNMET NEEDS AND OPPORTUNITIES
    7.1.3. MARKET SIZE (2017), FORECAST (2018-2028)
    7.2. INJECTABLES
    7.2.1. MARKET TRENDS AND GROWTH FACTORS
    7.2.2. UNMET NEEDS AND OPPORTUNITIES
    7.2.3. MARKET SIZE (2017), FORECAST (2018-2028)
    7.3. INHALATION
    7.3.1. MARKET TRENDS AND GROWTH FACTORS
    7.3.2. UNMET NEEDS AND OPPORTUNITIES
    7.3.3. MARKET SIZE (2017), FORECAST (2018-2028)
    8 GLOBAL TYPE-1 DIABETES THERAPEUTIC MARKET BY AGE GROUP
    8.1. ADULTS
    8.1.1. MARKET TRENDS AND GROWTH FACTORS
    8.1.2. UNMET NEEDS AND OPPORTUNITIES
    8.1.3. ADULT T1D MARKET SIZE (2017), FORECAST (2018-2028)
    8.2. ADOLESCENTS
    8.2.1. MARKET TRENDS AND GROWTH FACTORS
    8.2.2. UNMET NEEDS AND OPPORTUNITIES
    8.2.3. ADOLESCENT T1D MARKET SIZE (2017), FORECAST (2018-2028)
    8.3. PEDIATRIC
    8.3.1. MARKET TRENDS AND GROWTH FACTORS
    8.3.2. UNMET NEEDS AND OPPORTUNITIES
    8.3.3. PEDIATRIC T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9 TYPE-1 DIABETES THERAPEUTIC MARKET BY GEOGRAPHY
    9.1. UNITED STATES
    9.1.1. MARKET TRENDS AND GROWTH FACTORS
    9.1.2. UNMET NEEDS AND OPPORTUNITIES
    9.1.3. US T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9.2. UNITED KINGDOM
    9.2.1. MARKET TRENDS AND GROWTH FACTORS
    9.2.2. UNMET NEEDS AND OPPORTUNITIES
    9.2.3. UK T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9.3. GERMANY
    9.3.1. MARKET TRENDS AND GROWTH FACTORS
    9.3.2. GERMANY T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9.4. FRANCE
    9.4.1. MARKET TRENDS AND GROWTH FACTORS
    9.4.2. UNMET NEEDS AND OPPORTUNITIES
    9.4.3. FRANCE T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9.5. ITALY
    9.5.1. MARKET TRENDS AND GROWTH FACTORS
    9.5.2. UNMET NEEDS AND OPPORTUNITIES
    9.5.3. ITALY T1D MARKET SIZE (2017), FORECAST (2018-2028)
    9.6. SPAIN
    9.6.1. MARKET TRENDS AND GROWTH FACTORS
    9.6.2. UNMET NEEDS AND OPPORTUNITIES
    9.6.3. SPAIN MARKET SIZE (2017), FORECAST (2018-2028)
    9.7. JAPAN
    9.7.1. MARKET TRENDS AND GROWTH FACTORS
    9.7.2. UNMET NEEDS AND OPPORTUNITIES
    9.7.3. JAPAN MARKET SIZE (2017), FORECAST (2018-2028)
    9.8. CHINA
    9.8.1. MARKET TRENDS AND GROWTH FACTORS
    9.8.2. UNMET NEEDS AND OPPORTUNITIES
    9.8.3. CHINA MARKET SIZE (2017), FORECAST (2018-2028)
    9.9. INDIA
    9.9.1. MARKET TRENDS AND GROWTH FACTORS
    9.9.2. UNMET NEEDS AND OPPORTUNITIES
    9.9.3. INDIA MARKET SIZE (2017), FORECAST (2018-2028)
    9.10. BRAZIL
    9.10.1. MARKET TRENDS AND GROWTH FACTORS
    9.10.2. UNMET NEEDS AND OPPORTUNITIES
    9.10.3. BRAZIL TID MARKET SIZE (2017), FORECAST (2018-2028)
    9.11. RUSSIA
    9.11.1. MARKET TRENDS AND GROWTH FACTORS
    9.11.2. UNMET NEEDS AND OPPORTUNITIES
    9.11.3. RUSSIA MARKET SIZE (2017), FORECAST (2018-2028)
    9.12. ROW
    9.12.1. MARKET TRENDS AND GROWTH FACTORS
    9.12.2. UNMET NEEDS AND OPPORTUNITIES
    9.12.3. ROW MARKET SIZE (2017), FORECAST (2018-2028)
    10 CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    10.1. ESTABLISHED COMPANIES
    10.1.1. NOVO NORDISK A/S
    10.1.2. ELI LILLY AND COMPANY
    10.1.3. SANOFI
    10.1.4. MERCK
    10.1.5. BAYER PHARMACEUTICALS
    10.1.6. ASTELLAS PHARMA
    10.1.7. ASTRAZENECA
    10.1.8. ZEALAND PHARMA
    10.2. EMERGING COMPANIES
    11 ABBREVIATIONS

    LIST OF TABLES

    TABLE 1: LIST OF FDA APPROVED DRUGS FOR T1D
    TABLE 2: LIST OF EMA APPROVED DRUGS
    TABLE 3: CHARACTERISTIC COMPARISION OF TYPE-1 DIABETES AND TYPE-2 DIABETES
    TABLE 4: GLYCEMIC GOALS OF THERAPY
    TABLE 5: PHARMACOKINETIC PROPERTIES OF INSULIN PRODUCTS
    TABLE 6: T1D EPIDEMIOLOGY (2017), FORECAST (2018-2025)
    TABLE 7: MAJOR ACQUISITIONS AND MERGERS IN T1D THERAPEUTIC AREA SINCE 2009
    TABLE 8: MAJOR COLLABORATIVE AGREEMENTS IN T1D THERAPEUTIC AREA
    TABLE 9: MAJOR LICENSING AGREEMENTS IN T1D THERAPEUTIC AREA
    TABLE 10: MAJOR PARTNERSHIPS AND JOINT VENTURE IN T1D THERAPEUTIC AREA
    TABLE 11: MAJOR GRANTS AND FUNDING IN T1D THERAPEUTIC AREA
    TABLE 12: MAJOR ALLIANCE IN T1D THERAPEUTIC AREA
    TABLE 13: US FDA APPROVED DRUGS FOR T1D
    TABLE 14: EMA APPROVED DRUGS FOR T1D
    TABLE 15: FIASP PATENTS
    TABLE 16: TRESIBA EXCLUSIVITY
    TABLE 17: RYZODEG PATENTS
    TABLE 18: TOUJEO PATENTS
    TABLE 19: PRE-REGISTRATION (FILED) MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 20: PHASE 3 MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 21: PHASE 2 MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 22: PHASE 1 MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 23: PRECLINICAL MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 24: EARLY R&D MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 25: INACTIVE MOLECULES IN THE T1D DRUG PIPELINE
    TABLE 26: T1D DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 27: T1D DRUG PIPELINE MOLECULES BY INJECTABLE AS ROUTE OF ADMINISTRATION
    TABLE 28: T1D DRUG PIPELINE MOLECULES BY INFUSION AS ROUTE OF ADMINISTRATION
    TABLE 29: T1D DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
    TABLE 30: T1D DRUG PIPELINE MOLECULES BY INHALATION AS ROUTE OF ADMINISTRATION
    TABLE 31: T1D PIPELINE MOLECULES BELONGING TO INSULIN DRUG CLASS
    TABLE 32: VACCINES IN DEVELOPMENT FOR T1D
    TABLE 33: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 34: GLOBAL T1D THERAPEUTIC MARKET BY DRUG CLASS (2017-2028)
    TABLE 35: GLOBAL T1D THERAPEUTIC MARKET BY ROA (2017-2028)
    TABLE 36: STRENGTH, DOSAGE AND ROA OF T1D DRUGS
    TABLE 37: MEALTIME AFREZZA STARTING DOSE CONVERSION TABLE
    TABLE 38: TOP 10 COUNTRIES/TERRITORIES FOR NUMBER OF CHILDREN AND ADOLESCENTS DIAGNOSED WITH T1D DIABETES (<20 YEARS), 2017 TABLE 39: TOP 10 COUNTRIES/TERRITORIES FOR THE INCIDENCE RATES (PER 100,000 POPULATION PER YEAR) WITH T1D DIABETES (<20 YEARS), 2017 TABLE 40: GLOBAL T1D THERAPEUTIC MARKET BY AGE GROUP-ADULT MARKET SIZE (2017), FORECAST (2018-2028) TABLE 41: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF T1D DIABETES (CHILDREN AND ADOLESCENTS <20 YEARS), PER YEAR TABLE 42: GLOBAL T1D THERAPEUTIC MARKET BY AGE GROUP-ADOLESCENT MARKET SIZE (2017), FORECAST (2018-2028) TABLE 43: GLOBAL ESTIMATES FOR TYPE-1 DIABETES IN CHILDREN AND ADOLESCENTS (<20 YEARS) FOR 2017 TABLE 44: WHO RECOMMENDATIONS ON PHYSICAL ACTIVITY FOR DIFFERENT AGE GROUPS TABLE 45: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF T1D DIABETES (CHILDREN AND ADOLESCENTS <15 YEARS), PER YEAR TABLE 46: GLOBAL T1D THERAPEUTIC MARKET BY AGE GROUP-PEDIATRIC MARKET SIZE (2017), FORECAST (2018-2028) TABLE 47: GLOBAL T1D THERAPEUTIC MARKET BY GEOGRAPHY, MARKET SIZE (2017), FORECAST (2018-2028) TABLE 48: US MARKET SIZE (2017), FORECAST (2018-2028) TABLE 49: UK MARKET SIZE (2017), FORECAST (2018-2028) TABLE 50: INSULIN PRICE, PUBLIC AND PRIVATE SECTOR, MEAN PATIENT PRICE TABLE 51: GERMANY MARKET SIZE (2017), FORECAST (2018-2028) TABLE 52: FRANCE MARKET SIZE (2017), FORECAST (2018-2028) TABLE 53: T1D INCIDENCE RATES (PER 100,000) AMONG SUBJECTS <18 YEARS, APULIA, 2009-2013 TABLE 54: ITALY MARKET SIZE (2017), FORECAST (2018-2028) TABLE 55: DIABETES PREVALENCE IN SPAIN, ?18 YEARS, 2012 TABLE 56: SPAIN MARKET SIZE (2017), FORECAST (2018-2028) TABLE 57: JAPAN MARKET SIZE (2017), FORECAST (2018-2028) TABLE 58: MEAN PATIENT PRICE USD 10ML 100IU ANALOGUE INSULINS, CHINA TABLE 59: CHINA MARKET SIZE (2017), FORECAST (2018-2028) TABLE 60: INDIA MARKET SIZE (2017), FORECAST (2018-2028) TABLE 61: BRAZIL MARKET SIZE (2017), FORECAST (2018-2028) TABLE 62: RUSSIA MARKET SIZE (2017), FORECAST (2018-2028) TABLE 63: ROW MARKET SIZE (2017), FORECAST (2018-2028) TABLE 64: COMPANY OVERVIEW: NOVO NORDISK TABLE 65: MAJOR PRODUCTS: NOVO NORDISK A/S TABLE 66: COMPANY SNAPSHOT: ELI LILLY AND COMPANY TABLE 67: MAJOR PRODUCTS: ELI LILLY AND COMPANY TABLE 68: COMPANY SNAPSHOT: SANOFI TABLE 69: MAJOR PRODUCTS: SANOFI TABLE 70: COMPANY SNAPSHOT: MERCK TABLE 70: MAJOR PRODUCTS: MERCK TABLE 71: COMPANY SNAPSHOT: BAYER TABLE 72: MAJOR PRODUCTS: BAYER TABLE 73: COMPANY SNAPSHOT: ASTELLAS PHARMA TABLE 74: MAJOR PRODUCTS: ASTELLAS PHARMA TABLE 75: COMPANY SNAPSHOT: ASTRAZENECA TABLE 76: MAJOR PRODUCTS: ASTRAZENECA TABLE 77: COMPANY SNAPSHOT: ZEALAND PHARMA LIST OF FIGURES FIGURE 1: GLOBAL T1D MARKET 2017-2028: MARKET SNAPSHOT FIGURE 2: GLOBAL T1D MARKET BY GEOGRAPHY 2017 V/S 2028 FIGURE 3: T1D MARKET BY ROA, 2017 FIGURE 4: T1D MARKET BY AGE GROUP, 2017 FIGURE 5: KEY INFLECTION POINTS IN T1D MARKET (2010-2028) FIGURE 6: T1D MAJOR FINDINGS FIGURE 7: REGIONAL COMPARISON OF ESTIMATES FOR T1D FOR THE YEAR 2000 AND 2017 FIGURE 8: MEDICAL EXPENDITURES FOR DIABETES FIGURE 8: MECHANISM OF INSULIN PRODUCING PANCREAS IN TYPE-1 DIABETES FIGURE 9: PROPOSED SCHEME OF NATURAL HISTORY OF ?ETA- CELL DEFECT FIGURE 10: ETIOLOGIC CLASSIFICATION OF TYPE-1 DIABETES FIGURE 11: MANAGING T1D IN ADULTS FIGURE 12: T1D EPIDEMIOLOGY (2017), FORECAST (2018-2025) FIGURE 13: OVERALL DEALS ACTIVITY IN T1D THERAPEUTIC AREA FIGURE 14: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE FIGURE 15: T1D DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT FIGURE 16: T1D DRUG PIPELINE ANALYSIS BY GEOGRAPHY FIGURE 17: T1D DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES FIGURE 18: TOP 10 COUNTRIES WITH HIGHEST PREVALENCE OF T1D IN CHILDREN AGED LESS THAN 20 YEARS FIGURE 19: T1D DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINSTRATION FIGURE 20: DRUG CLASS CLASSIFICATION OF T1D DRUG PIPELINE FIGURE 21: MAJOR OTHER DRUG CLASSES OF T1D FIGURE 22: GRAPHICAL REPRESENTATION OF GLOBAL T1D THERAPEUTIC MARKET BY DRUG CLASS (2017-2028) FIGURE 23: GRAPHICAL REPRESENTATION OF GLOBAL T1D THERAPEUTIC MARKET BY ROA (2017-2028) FIGURE 24: T1D PREVALENCE BY AGE GROUP IN THE US, 2017 TABLE 25: GRAPHICAL REPRESENTATION, US MARKET SIZE 2017 V/S 2028 FIGURE 26: AGE AND GENDER OF PATIENTS WITH T1D DIABETES IN ENGLAND AND WALES, 2016-17 FIGURE 27: UK TREND OF ANALOGUE INSULIN AND HUMAN INSULIN, 2000-2009 TABLE 28: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2017 V/S 2028 FIGURE 29: PREVALENT CASES OF T1D IN GERMANY FOR LESS THAN 20 YEARS OF AGE, 2013-2017 TABLE 30: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2017 V/S 2028 FIGURE 31: NUMBER OF FRENCH DIABETIC PATIENTS TAKING ANTIDIABETIC MEDICATIONS, (2014, 2016) FIGURE 32: FRANCE VERSUS GERMANY, CONSUMPTION OF ANTIDIABETIC DRUGS IN DEFINED DAILY DOSE (DDD) PER 1,000 INHABITANTS PER DAY, 2011 FIGURE 33: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2017 V/S 2028 FIGURE 34: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2017 V/S 2028 FIGURE 35: INCIDENCE OF T1D AMONG CHILDREN IN SPAIN (PER 1,000 INHABITANTS) FIGURE 36: T1D ANNUAL COSTS DISTRIBUTION IN SPAIN FIGURE 37: ANNUAL AGE-WISE T1D COSTS IN SPAIN, 2014 FIGURE 38: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2017 V/S 2028 FIGURE 39: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2017 V/S 2028 FIGURE 40: T1D NEW CASES IN CHINA, 2017 FIGURE 41: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2017 V/S 2028 FIGURE 42: NEW T1D CASES IN CHINA, 2017 FIGURE 43: NUMBER OF UNDIAGNOSED, T1D, INDIA, 2015-2017 FIGURE 44: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2017 V/S 2028 FIGURE 45: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2017 V/S 2028 FIGURE 46: NEW T1D CASES IN RUSSIA, 2017 FIGURE 47: PREVALENCE V/S INCIDENCE IN RUSSIA, T1D, 2011 FIGURE 48: DIABETES DIRECT COST DISTRIBUTION IN RUSSIA FIGURE 49: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2017 V/S 2028 FIGURE 50: COUNTRY-WISE DIABETES PREVALENCE FIGURE 51: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2017 V/S 2028 FIGURE 52: ANNUAL REVENUE; ELI LILLY FIGURE 53: REVENUE ACROSS THE SEGMENTS ($ M): ELI LILLY AND COMPANY FIGURE 54: HUMAN PHARMACEUTICAL PRODUCTS: ELI LILLY AND COMPANY FIGURE 55: THE DISTRIBUTION OF SALES DEPENDING ON THE REVENUE GAINED: SANOFI FIGURE 56: BUSINESS OVERVIEW: ASTELLAS PHARMA FIGURE 57: ANNUAL GEOGRAPHICAL SALES ($ BN) : ASTELLAS PHARMA FIGURE 58: BUSINESS PERFORMANCE: ASTRAZENECA

Pricing

Individual Pricing $3500

Corporate Pricing $3500

Enterprise Pricing $3500

(We are offering all the above license types for a single price!!)